Pubblicazioni

Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature

2022 - CANCER TREATMENT REVIEWS

Lombardi, P.; Rossini, D.; Crespi, V.; Germani, M. M.; Bergamo, F.; Pietrantonio, F.; Santini, D.; Allegrini, G.; Daniel, F.; Pagani, F.; Antoniotti, C.; Zaniboni, A.; Conca, V.; Latiano, T. P.; Boccaccino, A.; Passardi, A.; Tamburini, E.; Masi, G.; Di Maio, M.; Cremolini, C.

Optical coherence tomography angiography in treated type 2 neovascularization undergoing monthly anti-VEGF treatment

2017 - ACTA OPHTHALMOLOGICA

Parravano, Mariacristina; Querques, Lea; Scarinci, Fabio; Giorno, Paola; De Geronimo, Daniele; Gattegna, Roberto; Varano, Monica; Bandello, Francesco; Querques, Giuseppe

The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma

2017 - JOURNAL OF HEMATOLOGY & ONCOLOGY

Gravina, Giovanni Luca; Mancini, Andrea; Marampon, Francesco; Colapietro, Alessandro; Delle Monache, Simona; Sferra, Roberta; Vitale, Flora; Richardson, Peter J.; Patient, Lee; Burbidge, Stephen; Festuccia, Claudio

Bevacizumab as first-line treatment in HER2-negative advanced breast cancer. Pros and cons

2016 - TUMORI

Sini, Valentina; Cassano, Alessandra; Corsi, Domenico; De Laurentiis, Michele; Gamucci, Teresa; Mauri, Mariella; Naso, Giuseppe; Roselli, Mario; Ruggeri, Enzo Maria; Tonini, Giuseppe; Vici, Patrizia; Zampa, Germano; Marchetti, Paolo